Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Plus SBRT in Oligometastatic Colorectal Cancer
NCT03927898Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in metastatic colorectal cancer (mCRC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 1 year. Status: unknown.
02
Drugs
toripalimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03927898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927898.